Could a common diabetes drug slow cataracts?
NCT ID NCT07176338
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This pilot study looks at whether metformin, a standard diabetes medicine, gets into the lens capsule of the eye and can slow the growth of lens cells that cause cataracts. Researchers will collect blood and lens tissue from 40 people with type 2 diabetes and age-related cataracts who already take metformin. The goal is to measure metformin levels in the lens and see if it reduces lens cell growth in lab tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- metformin
- What this could lead to
- If successful, this could point toward a way to slow cataract formation in people with diabetes.
- What could go wrong
- This is a very early, small pilot study (40 people) that only tests cells in a lab, not in the eye. It may not lead to any treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED CATARACT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vienna Institute for Research in Ocular Surgery (VIROS)
Vienna, 1140, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple stress ball or favorite tune replace anxiety meds during eye surgery?
- Can a bangkok community eye check reveal hidden glaucoma risks?
- Can a heart drug tame blood sugar and weight in diabetes?
- Can a puff of insulin replace a needle for diabetes?
- Could a quick insulin shot stop Steroid-Induced blood sugar spikes?
- Can a puff of insulin replace a daily shot for diabetes?